Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant

American Journal of Perinatology

Volumn 23, Issue 5, 2006, Pages 313-317

  Bass, J Kirk ^a   Faix, Roger G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin receptor antagonist; Fetotoxicity; Inhibitor; Nephrogenesis; Newborn infant; Renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CITRATE SODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; HYDROCORTISONE; LOSARTAN;

ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DRUG EFFECT; FETOTOXICITY; HIGH RISK INFANT; HUMAN; INFANT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY TUBULE ACIDOSIS; MEAN ARTERIAL PRESSURE; OLIGOHYDRAMNIOS; PREMATURITY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; KIDNEY FAILURE; LOSARTAN; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RENAL INSUFFICIENCY;

EID: 33745700982     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947162     Document Type: Article

References (34)

1. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409
2. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med 1993; 118:643-644
3. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type-II diabetic patients. Ann Intern Med 1993;118:577-581
4. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279
5. Khedun SM, Maharaj B, Moodley J. Effects of antihypertensive drugs on the unborn child -what is known, and how should this influence prescribing? Paediatr Drugs 2000;2:419-436
6. Pryde PG, Sedman AB, Nugent CE. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993;3:1575-1582
7. Hinsberger A, Wingen A-M, Hoyer PF. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1620
8. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 2001;357:363
9. Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001;358:241-242
10. Lambot M-A, Vermeylen D, Noel J-C. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1619-1620
11. Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1620-1621
12. Serreau R, Luton D, Macher M-A, Delezoide A-L, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type I receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005;112:710-712
13. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 2003;23:254-255
14. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 2003;67:591-594
15. Chow KM, Lam CM. Angiotensin II receptor antagonist in pregnancy. J Perinatol 2004;24:56-57
16. Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 2005;39:157-160
17. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res Part A Clin Mol Teratol 2005;73:123-130
18. Nayar B, Singhal A, Aggarwal R, Malhotra N. Losartan induced fetal toxicity. Indian J Pediatr 2003;70:923-924
19. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001;35:859-861
20. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. BJOG 2003;110:1038
21. Mann R, Mackay F, Pearce G, Freemantle S, Wilton L. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens 1999;13:551-557
22. Wolf G. Angiotensin II and tubular development. Nephrol Dial Transplant 2002;17(suppl 9):48-51
23. Prevot A, Mosig D, Guignard J-P. The effects of losartan on renal function in the newborn rabbit. Pediatr Res 2002;51: 728-732
24. Garcia-Villalba P, Denkers ND, Wittwer CT, Hoff C, Nelson RD, Mauch TJ. Real-time PCR quantification of AT1 and AT2 angiotensin receptor mRNA expression in the developing rat kidney. Nephron Exp Nephrol 2003;94:e154-e159
25. Chen Y, Lasaitiene D, Friberg P. The renin-angiotensin system in kidney development. Acta Physiol Scand 2004;181: 529-535
26. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392
27. Lip GYH, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 1997;350:1446-1447
28. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep 1997;46:240-242
29. Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS. Defining the susceptible period of developmental toxicity for the AT-1 selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367-382
30. Montouris G. Gabapentin exposure in human pregnancy: results from the gabapentin pregnancy registry. Epilepsy Behav 2003;4:310-317
31. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005;46: 1621-1624
32. Chambers CD, Kao KK, Felix RJ, et al. Pregnancy outcome in infants prenatally exposed to newer anticonvulsants. Birth Defects Res Part A Clin Mol Teratol 2005;73:316
33. Iqbal MM, Gundlapalli SP, Ryan WG, Ryals T, Passman TE. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J 2001;94:304-322
34. Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia 2003;44(suppl 3):33-40